

Deficiency In Serum Ionized Magnesium But Not Total Magnesium In Patients With Migraines. Possible Role Of ICa^{2+}/IMg^{2+} Ratio

A. Mauskop, M.D.^{1,3}, B.T. Altura, Ph.D.², R.Q. Cracco, M.D.¹, B.M. Altura, Ph.D.²

¹Departments of Neurology

²Physiology, State University of New York, Health Science Center at Brooklyn,

³New York Headache Center.

Send all correspondence and reprint requests to: Dr. B.M. Altura, Box 31, SUNY-Health Science Center, 450 Clarkson Avenue, Brooklyn, NY 11203-2098

Accepted for publication: November 26, 1992

SYNOPSIS

It has been suggested that magnesium (Mg) may play a role in the pathogenesis of headaches. Serum and intracellular measurements of Mg in headache patients have produced inconsistent results. The recent development of an ion-selective electrode for Mg^{2+} allowed precise measurement of serum ionized magnesium (IMg^{2+}) in patients with various headache syndromes. Low serum IMg^{2+} and a high ICa^{2+}/IMg^{2+} ratio were found in 42% of patients having an attack of migraine, but only in 23% of patients with a severe continuous headache. Total serum Mg was normal in both groups of patients. However, in patients with low serum IMg^{2+} total serum Mg was lower than in patients with normal serum IMg^{2+} . These results are compatible with the serotonin and vascular concepts of migraine pathogenesis. Low IMg^{2+} and a high ICa^{2+}/IMg^{2+} would result in cerebral vasospasm and reduced blood flow in the brain. The activity of serotonin receptors can also be affected by changes in IMg^{2+} levels. The finding of a difference in IMg^{2+} levels in two different headache types suggests a possible novel classification of headaches and that migraine patients with a low serum IMg^{2+} or a high ICa^{2+}/IMg^{2+} ratio may benefit from Mg supplementation.

Key words: Magnesium, calcium, headache, migraine, pathogenesis, classification.

(*Headache* 1993; 33:135-138)

INTRODUCTION

Due to lack of any objective measure the current International Headache Society (IHS) classification of headaches¹ is purely descriptive. A significant proportion of patients cannot be classified by this classification.² Diagnostic categories usually do not predict the efficacy of a certain treatment. For example, both migraines and chronic tension headaches may respond to tricyclic anti-depressants, while an acute severe headache of any type may respond to dihydroergotamine. Magnesium (Mg) may be one of the biological markers that can be used to classify headache types and, possibly, treat some of the patients.

Magnesium has long been implicated in the pathogenesis of headaches.³⁻⁷ Several anecdotal reports³⁻⁵ and one double-blind, placebo controlled trial⁸ showed therapeutic efficacy of Mg supplementation in headache patients. One study found total serum Mg levels to be decreased in migraine and tension-type headache patients during an attack more than in the interictal period.⁹ Two other studies showed normal serum levels of total Mg between attacks of migraine.^{8,10} One of these studies demonstrated decreased total Mg concentration in erythrocytes,¹⁰ while the other one found decreased Mg concentration in lymphocytes and polymorphonuclear cells, but not erythrocytes.⁸ Investigation using in vivo ³¹P nuclear magnetic resonance spectroscopy showed low brain Mg during and between migraine attacks in a few subjects.¹¹

We postulated that changes in serum IMg^{2+} rather than in total serum Mg or tissue levels of Mg may reflect metabolic disturbances in a migraine attack. Until recently there was no direct way to precisely determine serum IMg^{2+} levels. Development of an ion-selective electrode for IMg^{2+} ,^{12,13} allowed us for the first time to precisely and rapidly measure levels of IMg^{2+} in the serum of patients with various types of headaches.

SUBJECTS AND METHODS

After an informed consent 121 consecutive patients seen at a headache clinic had their blood drawn anaerobically to maintain a normal pH. Patients who had multiple or serious medical problems or were unable to rate their headache intensity were not included in this study. The laboratory personnel were blinded as the blood samples were not accompanied by any clinical information. Serum levels of IMg^{2+} and ICa^{2+} were measured using ion-selective electrodes with a NOVA Biomedical Stat Profile 8 Analyzer.^{12,13} The accuracy of these electrodes is 97-100%.^{12,13} Total Mg in the serum was determined by atomic absorption spectroscopy and a Kodak DT-60 Ektachem Analyzer, which yield identical results.¹³ Percent IMg^{2+} ($\%IMg^{2+}$) and ICa^{2+}/IMg^{2+} ratios were calculated. Mean values \pm S.E.M. were calculated and compared for statistical

significance by a non-paired Student's t-test, ANOVA and Scheffe's contrast test, where appropriate. A P value of less than 0.05 was considered significant.

An attempt was made to classify all patients according to the IHS criteria, but of 121 patients 18 (15%) were not classifiable. Twelve of these 18 patients fulfilled criteria for migraine headache, but the headache was continuous (they arguably could be classified as having status migrainosus). We selected for comparison 2 groups of patients. Patients in both groups had a severe headache within 24 hours of blood sampling. Severe headache was defined as greater than 5 on a verbal scale of 1 to 10. Thirty-three patients who were in the first group suffered from intermittent migraines, while the 13 patients in second group had continuous, daily headaches. In the continuous group 9 patients had nonclassifiable headaches of migrainous type and 4 patients had a daily chronic tension-type headache. The duration of headaches in the continuous group was 1 month in 3 and 5 months in 1 patient, while the rest had them for over a year. Sixty healthy (headache-free) faculty, staff and students volunteered to serve as controls.

RESULTS

Mean serum levels of IMg^{2+} , ICa^{2+} , $\% \text{IMg}^{2+}$ and $\text{ICa}^{2+}/\text{IMg}^{2+}$ are shown in Table 1 and Figure 1. Mean values of IMg^{2+} , total Mg and $\text{ICa}^{2+}/\text{IMg}^{2+}$ are compared in Figure 1. Only three of 13 patients (23%) in the continuous group had a low IMg^{2+} level, while 14 of 33 (42%) in the intermittent group had low IMg^{2+} levels ($P < 0.01$, chi-square). When patients with intermittent migraines were divided into subgroups with normal and low IMg^{2+} levels they formed two distinct groups. The group with a low serum IMg^{2+} also had a high $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratio. The patients with a continuous headache and a sub-group of patients with intermittent migraines had no significant disturbance of IMg^{2+} or $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratios, but tended to show lowered $\% \text{IMg}^{2+}$ relative to total Mg concentration (Table 1). The other subgroup of patients with intermittent migraines had a low IMg^{2+} level and a high $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratio as well as lowered $\% \text{IMg}^{2+}$. Total serum Mg levels were normal in all groups, but patients with intermittent migraines and a low IMg^{2+} level had significantly lower total Mg levels compared to other migraine subgroups.

DISCUSSION

The clear difference in serum IMg^{2+} values between patients with migraine attacks and continuous headaches suggests a different mechanism of pathogenesis of headaches in these two groups. One of several possible ways for Mg to affect the development of headaches is through its effect on vascular tone.⁶ It has been long suggested that migraine pathogenesis may involve both cerebral vasospasm and vasodilatation.^{6,7,14} Recently, a serotonin hypothesis has become more popular.¹⁵⁻⁻¹⁷ Modulation of serotonin receptors is now thought to be an important step in the development of migraines. Both the vascular and the serotonin aspects of migraine pathogenesis can be influenced by Mg. Experimentally, vasoconstriction is

Table 1
Mean Values \pm S.E.M. for patients with a continuous headache and during an intermittent migraine attack. These two groups are sub-divided into those with low and normal serum IMg^{2+} levels. Patients with a severe, continuous headache or a severe migraine attack within 48 hours of blood sampling were selected from 121

Group	N	IMg^{2+} (mM)	ICa^{2+} (mM)	Total Mg (mM)	$\% \text{IMg}^{2+}$
Controls	60	0.59 ± 0.005	1.19 ± 0.015	0.81 ± 0.008	71.6 ± 0.58
Intermittent Migraine	33	$0.556 \pm 0.009^*$	1.23 ± 0.007	0.836 ± 0.012	$66.5 \pm 0.63^*$
A. Low IMg^{2+}	14	$0.50 \pm 0.007^*$	1.22 ± 0.014	$0.78 \pm 0.015^{**}$	$64.6 \pm 0.75^*$
B. Normal IMg^{2+}	19	0.611 ± 0.017	1.24 ± 0.007	0.876 ± 0.012	$67.9 \pm 0.83^*$
Continuous Severe	13	0.567 ± 0.013	1.22 ± 0.008	0.86 ± 0.019	$66.0 \pm 1.03^*$
A. Low IMg^{2+}	3	$0.517 \pm .003^{**}$	1.22 ± 0.027	0.846 ± 0.013	$62.0 \pm 1.00^*$
B. Normal IMg^{2+}	10	0.582 ± 0.013	1.22 ± 0.007	0.861 ± 0.024	$67.6 \pm 0.98^*$

*Significantly diff. from controls ($p < 0.01$); *Sig. diff. from all groups except low continuous severe ($p < 0.01$).
** Sig. diff. from all migraine subgroups ($p < 0.01$). **Sig. diff. from all groups except low intermittent migraine ($p < 0.01$).




Fig. 1—Comparison of serum IMg^{2+} levels, $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratios and serum total Mg levels in patients with low and normal IMg^{2+} . Bars—mean values \pm S.E.M.

facilitated by a lowering of the extracellular levels of IMg^{2+} decreasing the gradient of IMg^{2+} or, possibly, by increasing the gradient of $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratio across the vascular smooth muscle cell membranes,¹⁸⁻²² thus causing a rise in intracellular free Ca^{2+} .^{23,24} IMg^{2+} levels may influence calcium channels and the intracellular ICa^{2+} levels, which in turn control vascular tone.^{25,26} This may be the mechanism of headache prevention by calcium channel blockers.²⁷⁻²⁹ Serotonin receptor activity could clearly be affected by IMg^{2+} concentration,³⁰⁻³² although the role of serotonin receptors in the development of migraine remains unclear. A low IMg^{2+} level could also facilitate the development of spreading depression of Leão,³³ which is thought to underlie the phenomenon of migraine aura.³⁴ IMg^{2+} could affect the development of headaches by modulation of N-methyl-D-aspartate (NMDA) re-ceptors.^{35,36} Lastly, the release of several other neurotransmitters is also controlled by the $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratio.³⁷ Thus, it is conceivable that changes in the $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratio may therefore be more important in the development of headaches than IMg^{2+} or the total Mg level.

Our findings support and possibly combine both the vascular and the serotonin theories of migraine pathogenesis.

Artificially lowering the Mg content of cerebral blood vessels in vivo and in vitro induces calcium-mediated vasospastic responses, while elevation in $[\text{Mg}^{2+}]$ reduces vascular tone.¹⁸⁻²² A lowering of IMg^{2+} and an elevation of the $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratio would have three effects on serotonin action: 1. an increased affinity for serotonin cerebral vascular muscle receptor sites;³⁰⁻³² 2. a potentiation of cerebral vasoconstriction induced by serotonin;¹⁸⁻²² and 3. a facilitation of 5-HT release from neuronal storage sites.³⁷ Finally, a decrease in serum and tissue Mg, at intermittent times, as has been reported by several groups⁸⁻¹¹ could create a situation favoring vascular vasodilatation followed by a sustained contraction mediated by endothelium-derived relaxant factors.³⁸⁻⁴⁰ The latter would explain the biphasic vasomotor changes in cerebral vascular tone seen in migraine.^{6,7,17,41,42}

The deficit in serum IMg^{2+} levels or an increase in the $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratio may, thus, be two of the triggering factors that set off a migraine attack in susceptible individuals. Serotonin receptors (and possibly other neurotransmitters) and blood vessels are the likely mediators of the clinical syndrome that follows. Alternatively, it is possible that this alteration of Mg metabolism is not the initiating event, but is secondary to other biochemical phenomena. Frequent, sequential measurements of serum IMg^{2+} levels and $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratios immediately before, during and after migraine attacks would be difficult to do, but could provide this information.

The susceptibility to migraines, at least in part, could be genetic in nature as suggested by the high incidence of familial clustering of this condition and by the twin studies.^{43,44} Cellular Mg content and magnesium metabolism are under genetic control as well,⁴⁵ and it is conceivable that the heredity of migraines and magnesium metabolism overlap.

The observed normal level of IMg^{2+} in 10 out of 13 patients with continuous headaches indicates that the process of transformation of intermittent headaches into a continuous one either does not involve a disturbance of Mg metabolism or is accompanied by a normalization of Mg metabolism. Continuous headaches may represent a type of central pain syndrome where more subtle neurotransmitter changes are involved in pain perception and its perpetuation. Clinical experience supports this speculation. Abortive medications (analgesics, ergots, combinations of drugs) are usually ineffective in this type of headaches. Overuse of abortive medications is one of the possible causes of transformation of intermittent headaches into a continuous one.⁴⁶⁻⁴⁸ Of our 13 patients with continuous headaches 4 were regularly taking this type of medication.

In conclusion, this paper demonstrates that in 42% of patients with an acute migraine attack serum IMg^{2+} levels are low, while the $\text{ICa}^{2+}/\text{IMg}^{2+}$ ratio is high. By comparison only 23% of patients with continuous headaches had a low serum IMg^{2+} level. The use of an ion-selective electrode for Mg^{2+} should allow further elucidation and differentiation of the pathogenesis of headaches by determining serum IMg^{2+} , ICa^{2+} , $\% \text{IMg}^{2+}$ and $\text{ICa}^{2+}/\text{IMg}^{2+}$ in large groups of patients with various headache types. This may lead to the development of specific therapies for each headache type. Mg supplementation may be an effective treatment for one of the sub-groups of patients.

REFERENCES

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia* 1988; 8, Suppl 7:10-73.
2. Messinger HB, Spierings ELH, Vincent AJP. Overlap of migraine and tension-type headache in International Headache Society classification. *Cephalalgia* 1991; 11:233-237.
3. Simon KH. Magnesium: Physiologie, Pharmakologie, Klinik (Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1967).
4. Vosgerau H. Zur Behandlung der Migräne mit Magnesiumglutamat. *Therapie Gegenw* 1973; 112:640-648.
5. Weaver K. Magnesium and migraine; reversible hypomagnesic coagulative angiopathy, hypothesis and preliminary data (abstract). *J Am Coll Nutr* 1983; 2:287-288.
6. Altura BM. Calcium antagonist properties of magnesium: implications for antimigraine actions. *Magnesium* 1985; 4:169-175.
7. Swanson DR. Migraine and magnesium, eleven neglected connections. *Perspect Biol Med* 1988; 31 (4):526-537.

8. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. *Headache* 1991; 31:298-301.
9. Sarchielli P, Coata G, Firenze C, Morucci P, Abbritti G, Gallai V. Serum and salivary magnesium levels in migraine and tension-type headache. Results in a group of adult *Cephalalgia* 1992; 12:21-27.
10. Schoenen J, Sianard-Gainko J, Lenaerts M. Blood magnesium levels in migraine. *Cephalalgia* 1991; 11:97-99.
11. Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpem JA, Welch KMA. Low brain magnesium in migraine. *Headache* 1989; 29:590-593.
12. Altura BT, Dell'Ofrano K, Barbour RL, Yeh Q, Young CC, Hiti J, Welch R, Shirley T, Altura BM. Ionized magnesium (Mg^{2+}): Characteristics of a new ion selective electrode (ISE) for Mg for whole blood, plasma and serum. *FASEB J*. 1991; 5:A1309 (Abstr).
13. Altura BT, Shirley T, Young CC, Dell'Ofrano K, Hiti J, Welch R, Yeh Q, Barbour RL, Altura BM. Characteristics of a new ion selective electrode for ionized magnesium in whole blood, plasma and serum. *Clin Chem*, in press.
14. A. Rodella. Migräne und Hautgefäße. *Schweiz Med Woch-enschr* 1931; 61:1256.
15. Sicuteri F, Testi H, Anselmi B. Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. *Int Arch. Allergy* 1961; 19:55-58.
16. Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindole acetic acid and p-hydroxy-mmethoxymandelic acid excretion in normal and migrainous subjects. *Brain* 1965; 88:997-1007.
17. Lance JW. 5-Hydroxytryptamine and its role in migraine. *Eur Neurol* 1991; 31 (5):279-81.
18. Altura BM, Altura BT, Carella A. Magnesium deficiency induced spasms of umbilical vessels: relation to preeclampsia, hypertension, growth retardation. *Science* 1983; 221:376-378.
19. Altura BT, Altura BM. Withdrawal or magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries. *Neurosci Lett* 1980; 20:323-327.
20. Altura BT, Altura BM. The role of magnesium in etiology of strokes and cerebrovasospasm. *Magnesium* 1982; 1:277-291.
21. Altura BT, Altura BM. Interactions of Mg and K on blood vessels - aspects in view of stroke. *Magnesium* 1984; 3:195-211.
22. Huang QF, Gebrewold A, Altura BT, Altura BM. Cocaine-induced cerebral damage can be ameliorate by Mg^{2+} in rat brain. *Neurosci Lett* 1990; 109:113-116.
23. Turlapaty PDMV, Altura BM. Extracellular magnesium ions control calcium exchange and content of vascular smooth muscle. *Eur J Pharmacol* 1978; 52:421-423.
24. Zhang A, Cheng TPO, Altura BM. Magnesium regulates intracellular free ionized calcium concentration and cell geometry in vascular smooth muscle cell. *Biochim Biophys Acta* 1992; 1134:25-29.
25. Altura BM, Altura BT, Carella A, Murakawa T, Nishio A. Mg^{2+} - Ca^{2+} interaction in contractility of vascular smooth muscle: Mg^{2+} versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. *Canad J Physiol Pharmacol* 1987; 65:729-745.
26. White FIE, Hartzell HC. Magnesium ions in cardiac function. Regulator of ion channels and second messengers. *Biochem Pharmacol* 1989; 38:859-867.
27. Solomon GD, Spaccavento LJ. Verapamil prophylaxis of migraine: A double-blind, placebo controlled trial. *JAMA* 1983; 250:2502.
28. Markley H, Cheronis J, Piepho R. Verapamil prophylactic therapy of migraine. *Neurology* 1984; 34:973-976.
29. Steardo L, Marano E, Barone P, Denman DW, Monteleone P, Cardone G. Prophylaxis of migraine attacks with a calcium-channel blocker: Flunarizine versus methysergide. *J Clin Pharmacol* 1986; 26:524-528.
30. Turlapaty PDMV, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. *Science* 1980; 208:198-200.
31. Norman AB, Battaglia G, Creese I. [3H]WB4101 labels the 5-HT_{1A} serotonin receptor subtype in rat brain. *Mol Pharmacol* 1985; 28:487-494.
32. Peters JA, Hales TG, Lambert JJ. Divalent cations modulate 5-HT₃ receptor-induced currents in NIE-115 neuroblastoma cells. *Eur J Pharmacol* 1988; 151:491-495.
33. Mody I, Lambert JDC, Heinemann V. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. *J Neurophysiol* 1987; 57:869-888.
34. Milner PM. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leão. *Electroenceph Clin Neurophysiol* 1958; 10:705.
35. Foster AC, Fagg GE. Neurobiology. Taking apart NMDA receptors. *Nature* 1987; 329:395-396.
36. Reynolds IJ. Modulation of NMDA receptor responsiveness by neurotransmitters, drugs and chemical modification. *Life Sci* 1990; 47:1785-1792.
37. Sigel H, Sigel A. Eds., Metal Ions in Biological Systems, vol. 26: Compendium on magnesium and its role in biology, nutrition, and physiology. New York: Marcel Dekker, 1990.
38. Ku DD, Ann HS. Magnesium deficiency produces endothelium-dependent vasorelaxation in canine coronary arteries. *J Pharmacol Exp Ther* 1987; 241:961-966.
39. Altura BT, Altura BM. Endothelium-dependent relaxation in coronary arteries requires magnesium ions. *Brit J Pharmacol* 1987; 91:449-451.
40. Gold ME, Buga GM, Wood KS, Byrns RE, Chaudhuri G, Ignarro LI. Antagonistic modulatory roles of magnesium and calcium on release of endothelium-derived relaxing factor and smooth muscle tone. *Circ Res* 1990; 66:355-366.
41. Gulliksen G, Enevoldsen E. Prolonged changes in rCBF following attacks of migraine accompagnee. *Acta Neurol Scand* 1984; 69(suppl 98):270-271.
42. Andersen AR, Friberg L, Skyhøj Olsen T, Olsen J. Delayed hyperemia following hypoperfusion in classic migraine. *Arch Neurol* 1988; 45:154-159.
43. Bille B. Migraine in school children. *Acta Paediatr* 1962; 51(Suppl 136):1-151.
44. Harvald B, Hauge M. A catamnestic investigation of Danish twins - a preliminary report. *Dan Med Bull* 1956; 3:150-158.
45. Henrotte JG. Genetic regulation of red blood cell magnesium content and major histocompatibility complex. *Magnesium* 1982; 1:69-80.
46. Kudrow L. Paradoxical effects of frequent analgesic use. In: Critchley Met et al., editors. *Advances in Neurology*, New York: Raven Press, 1982; vol. 33:335-341.
47. Isler H. Migraine treatment as a cause of chronic migraine. In: Rose FC, editor. *Advances in migraine research and therapy*. New York: Raven Press, 1982:159-163.
48. Mathew NT, Kurman FI, Perez F. Drug induced refractory headache - clinical features and management. *Headache* 1990; 30:634-638.